SC1 - Health, demographic change and wellbeing
Responding to this challenge, research and innovation (R&I) under Horizon 2020 is an investment in better health for all. It aims to keep older people active and independent for longer and supports the development of new, safer and more effective interventions.
Your NCP contact for this programme
Lieve Apers
lieve.apers@vlaio.be
+32 497 59 33 58
About this programme
Responding to this challenge, research and innovation (R&I) under Horizon 2020 is an investment in better health for all. It aims to keep older people active and independent for longer and supports the development of new, safer and more effective interventions. R&I under Horizon 2020 also contributes to the sustainability of health and care systems.
Research & Innovation supported by this call will:
- improve our understanding of the causes and mechanisms underlying health, healthy ageing and disease;
- improve our ability to monitor health and to prevent, detect, treat and manage disease;
- support older persons to remain active and healthy;
- and test and demonstrate new models and tools for health and care delivery.
Latest news
Health Culture and society Security Digital, Industry & Space
Industry 5.0 Award 2023- open for submission
What: It is a non-monetary recognition for EU-funded projects. The winning project, as well as the two other finalists will receive communication support and visibility on the European Commission’s channels, including social media publicity and an article in the Horizon Magazine. For whom: Eligible projects must have obtained funding (o... read more
Upcoming events
Work Programme & Calls
Infosheets
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
-
No infosheets available for this domain
Related links
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents
Documents contain additional information related to this programme, and are similar to related links.
- Inno4Cov-19 _Press Release_First Open Call_Results
- Inno4Cov-19_First Open Call - A glance First Round_Results
- Inno4Cov-19 _ Second call _ Open Call-in-a-glance
- Detailed information about MOST call on COVID-19/Corona
- Funded Research projects on Coronavirus from call topic SC1-PHE-CORONAVIRUS-2020
- Corona/COVID - Solidarity with Europe – JRC science to tackle the coronavirus crisis
- Presentations - Health NCP Net 2.0 Training 18-19 October 2018
- Presentation Health Work programme 18-20, calls and topics
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
